8-K: Evolus Reports Record Q4 and Full Year 2024 Results, Reaffirms 2025 Guidance

Evolus announces record global net revenue of $79.0 million for Q4 2024 and $266.3 million for full year 2024, representing 30% and 32% growth respectively, and reaffirms its 2025 revenue guidance.

Summary

• Evolus reported record fourth quarter and full year 2024 financial results.
• Global net revenue reached $79.0 million for the fourth quarter and $266.3 million for the full year, representing 30% and 32% growth over the prior year, respectively.
• The company achieved GAAP operating loss improvement to $2.3 million for the fourth quarter and $34.4 million for the full year.
• Evolus achieved full-year profitability one year ahead of expectations with positive non-GAAP operating income of $0.3 million for FY 2024.
• The company expects to expand non-GAAP operating income margins and cash generation.
• Full-year 2024 non-GAAP operating expense was $185.0 million, at the low end of the expected guidance range of $185 million to $190 million.
• Evolysse received FDA approval in February for dynamic facial lines and folds.
• 2025 net revenue guidance is $345 million to $355 million, representing 30% to 33% growth from 2024 results.
• Evolysse and Estyme injectable HA gels are anticipated to contribute 8-10% of total revenue for the full-year 2025.
• The company expects to achieve non-GAAP operating income on a consolidated basis for the full-year 2025.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record revenues, profitability achieved ahead of schedule, and strong future guidance. The successful launch of new products and expansion into new markets further contribute to the positive sentiment.

Positives

• Evolus achieved full-year profitability ahead of expectations.
• The company delivered its fifth consecutive year of revenue growth exceeding 30%.
• Jeuveau continues to outperform the market, driven by strong consumer loyalty and increasing adoption.
• Evolysse received FDA approval for dynamic facial lines and folds in February 2025.
• Enrollment in the Evolus Rewards consumer loyalty program grew over 40% in 2024 to end the year at approximately 1.1 million consumers.
• Cash and cash equivalents on December 31, 2024 were $87.0 million compared to $85.0 million on September 30, 2024, reflecting strong sales growth, cash collections and prudent expense management.

Negatives

• GAAP operating expenses were $216.7 million in 2024 compared to $186.8 million in 2023.
• GAAP loss from operations was $34.4 million for 2024 compared to $49.2 million in 2023.

Risks

• The company's ability to comply with the terms and conditions in the Medytox Settlement Agreements is a risk.
• Unfavorable global economic conditions and the impact on consumer discretionary spending could affect results.
• Customer and consumer adoption of Jeuveau and Evolysse is subject to uncertainties.
• The company's ability to successfully launch and commercialize its products in new markets is a risk.
• The company's reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse HA gel products in the U.S. is a risk.

Future Outlook

Evolus anticipates net revenues between $345 million and $355 million for 2025, representing 30% to 33% growth from 2024, with Evolysse and Estyme contributing 8-10% of total revenue; the company expects to achieve positive non-GAAP operating income on a consolidated basis for the full year 2025 and projects total net revenue can reach at least $700 million by 2028.

Management Comments

• We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%, said David Moatazedi, President and Chief Executive Officer of Evolus.
• Jeuveau continues to outperform the market, driven by strong consumer loyalty and increasing adoption, and we are now entering 2025 focused on transforming Evolus into a multi-product, performance beauty company with the imminent launch of Evolysse.
• We are prepared to launch Evolysse in the second quarter and will be making significant investments in medical education and sampling to support our customers and drive adoption, with meaningful revenue contributions expected in the second half of the year, continued Moatazedi.
• With a path toward at least $700 million in net revenue and a non-GAAP operating income margin of at least 20% by 2028, we remain focused on delivering exceptional results and creating long-term value for our shareholders.

Industry Context

Evolus's focus on aesthetics and its expansion into HA gels positions it to compete in the growing market for non-invasive cosmetic procedures. The company's emphasis on a customer-centric business model and digital platform aligns with industry trends towards personalized and accessible beauty solutions.

Comparison to Industry Standards

• Evolus's revenue growth of 32% significantly outpaces the overall aesthetics market growth, suggesting strong market share gains.
• Companies like Allergan (now part of AbbVie) and Galderma are major players in the aesthetics market, and Evolus is aiming to capture a larger share through its innovative products and business model.
• The target of $700 million in net revenue by 2028 would position Evolus as a significant competitor in the aesthetics industry.
• The company's focus on non-GAAP operating income margins of at least 20% by 2028 is comparable to the profitability targets of established players in the aesthetics market.

Stakeholder Impact

• Shareholders can expect continued growth and profitability.
• Employees may benefit from the company's expansion and success.
• Customers will have access to new and innovative aesthetic products.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a more creditworthy borrower.

Next Steps

• Launch Evolysse Form and Evolysse Smooth in the U.S. market in Q2 2025.
• Continue to expand Jeuveau in the U.S.
• Scale Nuceiva internationally.
• Support the launch for Evolysse Form and Evolysse Smooth injectable HA gels.
• Introduce Estyme through a limited experience program with select physician partners in Europe.
• Broader European launch of Estyme in the second half of 2025.
• Launch Evolysse Sculpt in 2026.
• Launch Evolysse Lips in 2027.

Key Dates